S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
15 best consumer discretionary stocks for the rest of 2023
New CBOE “special perk” helps traders target income every weekend (Ad)
Energy traders: A rebound is coming
Kroger shares are begging to be bought 
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Behind the tech boom: Big price leaders selectively laying off
Dallas Mavericks purchase turns LVS stock into a cheaper bet
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
These biotechs targeting multiple neurodegenerative diseases
Earnings propel Crowdstrike, cybersecurity sector, to new highs
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
15 best consumer discretionary stocks for the rest of 2023
New CBOE “special perk” helps traders target income every weekend (Ad)
Energy traders: A rebound is coming
Kroger shares are begging to be bought 
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Behind the tech boom: Big price leaders selectively laying off
Dallas Mavericks purchase turns LVS stock into a cheaper bet
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
These biotechs targeting multiple neurodegenerative diseases
Earnings propel Crowdstrike, cybersecurity sector, to new highs
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
15 best consumer discretionary stocks for the rest of 2023
New CBOE “special perk” helps traders target income every weekend (Ad)
Energy traders: A rebound is coming
Kroger shares are begging to be bought 
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Behind the tech boom: Big price leaders selectively laying off
Dallas Mavericks purchase turns LVS stock into a cheaper bet
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
These biotechs targeting multiple neurodegenerative diseases
Earnings propel Crowdstrike, cybersecurity sector, to new highs
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
15 best consumer discretionary stocks for the rest of 2023
New CBOE “special perk” helps traders target income every weekend (Ad)
Energy traders: A rebound is coming
Kroger shares are begging to be bought 
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Behind the tech boom: Big price leaders selectively laying off
Dallas Mavericks purchase turns LVS stock into a cheaper bet
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
These biotechs targeting multiple neurodegenerative diseases
Earnings propel Crowdstrike, cybersecurity sector, to new highs

MediWound Stock Price, News & Analysis (NASDAQ:MDWD)

$8.85
-0.09 (-1.01%)
(As of 12/1/2023 ET)
Compare
Today's Range
$8.76
$8.96
50-Day Range
$7.58
$10.87
52-Week Range
$7.10
$14.58
Volume
17,852 shs
Average Volume
15,379 shs
Market Capitalization
$81.51 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$29.00

MediWound MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
227.7% Upside
$29.00 Price Target
Short Interest
Healthy
0.46% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.98mentions of MediWound in the last 14 days
Based on 7 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($1.33) to ($1.46) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.09 out of 5 stars

Medical Sector

515th out of 954 stocks

Medicinals & Botanicals Industry

4th out of 11 stocks


MDWD stock logo

About MediWound Stock (NASDAQ:MDWD)

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.

MDWD Stock Price History

MDWD Stock News Headlines

Trading Experts Call It “The Perfect Tesla Trade”
Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.
MediWound (NASDAQ:MDWD) Given Buy Rating at HC Wainwright
MediWound (NASDAQ:MDWD) Upgraded to "Hold" by StockNews.com
Recap: MediWound Q3 Earnings
Trading Experts Call It “The Perfect Tesla Trade”
Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.
MediWound Q3 2023 Earnings Preview
MediWound to Report Third Quarter 2023 Financial Results
MediWound Gets CHMP Positive Opinion for NexoBrid
MediWound Ltd MDWD
MediWound Deploys NexoBrid® for Emergency Supply
Maxim Group Sticks to Their Buy Rating for Mediwound (MDWD)
MediWound Announces Full Commercial Launch Of NexoBrid - Quick Facts
See More Headlines
Receive MDWD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MediWound and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/21/2023
Today
12/01/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
3/21/2024

Industry, Sector and Symbol

Industry
Medicinals & botanicals
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:MDWD
Employees
83
Year Founded
2001

Price Target and Rating

Average Stock Price Target
$29.00
High Stock Price Target
$36.00
Low Stock Price Target
$25.00
Potential Upside/Downside
+227.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-19,600,000.00
Pretax Margin
-49.27%

Debt

Sales & Book Value

Annual Sales
$26.50 million
Book Value
$3.59 per share

Miscellaneous

Free Float
8,359,000
Market Cap
$81.51 million
Optionable
Not Optionable
Beta
1.03

Social Links

5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

  • Mr. Ofer Gonen B.Sc. (Age 50)
    Chief Executive Officer
    Comp: $485k
  • Dr. Lior Rosenberg M.D. (Age 77)
    Co-Founder
    Comp: $727k
  • Dr. Ety Klinger MBA (Age 61)
    Ph.D., Chief Research & Development Officer
    Comp: $393k
  • Ms. Hani Luxenburg
    Chief Financial Officer
  • Mr. Tzvi Palash B.Sc. (Age 66)
    M.Sc., Chief Operating Officer
  • Mr. Yaron Meyer Adv. (Age 44)
    Executive VP, General Counsel & Corporate Secretary
    Comp: $240k
  • Mr. Barry J. Wolfenson (Age 56)
    Executive Vice President of Strategy & Corporate Development
  • Dr. Robert J. Snyder CWS (Age 73)
    D.P.M., F.A.C.F.A.S., FFPM, M.B.A., M.Sc., Chief Medical Officer














MDWD Stock Analysis - Frequently Asked Questions

Should I buy or sell MediWound stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for MediWound in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" MDWD shares.
View MDWD analyst ratings
or view top-rated stocks.

What is MediWound's stock price target for 2024?

4 equities research analysts have issued 1-year price targets for MediWound's shares. Their MDWD share price targets range from $25.00 to $36.00. On average, they predict the company's share price to reach $29.00 in the next year. This suggests a possible upside of 227.7% from the stock's current price.
View analysts price targets for MDWD
or view top-rated stocks among Wall Street analysts.

How have MDWD shares performed in 2023?

MediWound's stock was trading at $13.49 on January 1st, 2023. Since then, MDWD shares have decreased by 34.4% and is now trading at $8.85.
View the best growth stocks for 2023 here
.

Are investors shorting MediWound?

MediWound saw a decrease in short interest in the month of November. As of November 15th, there was short interest totaling 30,200 shares, a decrease of 20.9% from the October 31st total of 38,200 shares. Based on an average daily volume of 23,000 shares, the days-to-cover ratio is presently 1.3 days. Approximately 0.5% of the shares of the stock are short sold.
View MediWound's Short Interest
.

When is MediWound's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 21st 2024.
View our MDWD earnings forecast
.

How were MediWound's earnings last quarter?

MediWound Ltd. (NASDAQ:MDWD) issued its quarterly earnings results on Tuesday, November, 21st. The biopharmaceutical company reported ($0.24) earnings per share for the quarter, beating the consensus estimate of ($0.45) by $0.21. The biopharmaceutical company had revenue of $4.78 million for the quarter, compared to analyst estimates of $4.73 million. MediWound had a negative net margin of 49.79% and a negative trailing twelve-month return on equity of 44.32%. During the same quarter last year, the firm posted ($0.91) earnings per share.

When did MediWound's stock split?

MediWound shares reverse split on Tuesday, December 20th 2022. The 1-7 reverse split was announced on Tuesday, December 20th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, December 20th 2022. An investor that had 100 shares of stock prior to the reverse split would have 14 shares after the split.

What other stocks do shareholders of MediWound own?

Based on aggregate information from My MarketBeat watchlists, some companies that other MediWound investors own include OPKO Health (OPK), Sorrento Therapeutics (SRNE), Blackstone (BX), Dynavax Technologies (DVAX), Geron (GERN), Idera Pharmaceuticals (IDRA), Mastercard (MA), SCYNEXIS (SCYX), Vascular Biogenics (VBLT) and Wells Fargo & Company (WFC).

Who are MediWound's major shareholders?

MediWound's stock is owned by many different institutional and retail investors. Top institutional shareholders include Yelin Lapidot Holdings Management Ltd. (0.94%), Essex Investment Management Co. LLC (0.57%) and Concourse Financial Group Securities Inc. (0.00%).

How do I buy shares of MediWound?

Shares of MDWD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:MDWD) was last updated on 12/2/2023 by MarketBeat.com Staff

My Account -